You are partly correct and partly wrong about Bavi and HCV. a) The HCV monotherapy results were not adequate to support moving ahead as a monotherapy. This was also true of the cancer application of Bavi. Against cancer Bavi was not terribly effective as a monotherapy. But preclinical studies showed it was very effective in combination with many chemotherapies and with radiation in many indications. b) The company moved ahead with cancer trials using Bavi in combination with several chemotherapies against lung and breast cancers. The results were very good.They will be most likely fully reported at this years ASCO. They did not ignore HCV. Rather they ran a trial using Bavi in patients co-infected with HCV and HIV. They expect to report this mid-year. c) They are now running two phase II studies using combinations with chemo against lung cancer: another phase II using a different chemo against pancreatic cancer and yet another combination trial against liver cancer. d) They have ongoing studies in the anti-viral area with Duke University and the DTRA. These are in the HIV and haemoraggic fever areas. e) As well as the Phase I monotherapy study with HCV they also did preclinical studies of the combination of BAVI and ribavirin. For a while it may appear that they had lost interest in HCV. I don't think that was the case. They clearly have an interest in both cancer and anti-viral applications of Bavi. HCV is one of the viruses they have studied and now they feel ready to move into a combination Phase II study. I just wish them good luck in all their studies. The results are what are important. So far the combination study results have been very good.
Market Data 
Markets 
AI
